XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The Company also acquires milestone and royalty revenue streams on late-stage or commercial assets.
企業コードXOMA
会社名XOMA Royalty Corp
上場日Jun 06, 1986
設立日2011
最高経営責任者「CEO」Mr. Owen P. Hughes, Jr.
従業員数13
証券種類Ordinary Share
決算期末Jun 06
本社所在地2200 Powell Street
都市EMERYVILLE
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号94608
電話番号15102047239
ウェブサイトhttps://www.xoma.com/
企業コードXOMA
上場日Jun 06, 1986
設立日2011
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし